Through our innovative and proven technologies
, Greffex has invented the future of vaccines and genetic medicine. Our proprietary GREVAX™ Universal Platform
delivers vaccines in a faster and more efficient manner. Once a pathogen has been identified, Greffex’s team can design and produce a GREVAX vaccine
within 4 weeks. We have developed systems to manufacture enough vaccines within weeks to immunize the entire US population.
The flexibility of the GREVAX™ Universal Platform
makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains
, MERS-CoV, Anthrax
, Zika and Dengue Fever
, as well as Malaria, Hepatitis C, RSV Ebola, HPV, Tuberculosis and other infections.
Our GREVAX™ Universal Platform
in conjunction with Greffex’s proprietary engineered veto strategy allows the development of a new generation of immune evading gene therapy vectors and novel approaches to immune suppression in organ transplantation.